Celularity Inc. (CELU)
| Market Cap | 29.99M |
| Revenue (ttm) | 40.58M |
| Net Income (ttm) | -80.65M |
| Shares Out | 28.84M |
| EPS (ttm) | -3.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,069 |
| Open | 1.000 |
| Previous Close | 0.990 |
| Day's Range | 1.000 - 1.040 |
| 52-Week Range | 0.963 - 4.350 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+476.92%) |
| Earnings Date | May 11, 2026 |
About CELU
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscap... [Read more]
Financial Performance
In 2024, Celularity's revenue was $54.22 million, an increase of 138.11% compared to the previous year's $22.77 million. Losses were -$57.89 million, -70.51% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CELU stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
NEXGEL Appoints Ian Blackman as Chief Financial Officer
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or...
Celularity Announces Closing of Transaction with NexGel
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its...
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April 16,...
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today ...
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
The transaction represents the most significant milestone in the company's history.
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today ...
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Mi...
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under t...
Celularity Announces Closing of Financing Transactions
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, toda...
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, toda...
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, anno...
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, toda...
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compli...
Celularity Receives Nasdaq Notice Regarding Form 10-Q
FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and...
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V.
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative dis...
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025...
Celularity Announces Chief Financial Officer Transition
Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide out...
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative m...
Celularity Announces Full Year 2024 Operating and Financial Results
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, t...
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has not...
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers Action delays to January 1, 2026,...
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds Natalin and Acelagraft™...
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered ...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it has received...